Find news published in the date range below
and and
and and
and and
Clear
Euro
Arrow
53,9521
Dollar
Arrow
44,7277
Sterling
Arrow
63,0385
Gold
Arrow
6254,6045
BIST 100
Arrow
10.729

Uğur Şahin gives a date for the cancer vaccine

Prof. Dr. Uğur Şahin, co-founder and CEO of the German biotechnology firm BioNTech, announced that they expect the first mRNA-based cancer vaccines to be approved before 2030.

Don't leave your news choices to an algorithm - decide for yourself what you read. Add 12punto to your preferred sources!
Uğur Şahin gives a date for the cancer vaccine

Speaking to the German newspaper Bild am Sonntag, Uğur Şahin stated, "We expect our first mRNA-based cancer vaccines to be approved before 2030. We also plan to have trial data for other therapeutic approaches between 2025 and 2029."

Emphasizing that their goal is to develop personalized cancer vaccines for every patient, Şahin said, "To do this, we analyze the cancer characteristics of each patient and select those that will enable the immune system to recognize and destroy as many tumor cells as possible."

Pointing to antibody-drug conjugates (ADCs) as another source of hope, Şahin added, "ADCs are antibodies that carry chemotherapy. They circulate in the blood, reach the tumor, and release the chemotherapy there in a targeted manner. The importance of this treatment is that it can shrink the tumor very quickly in a significant portion of participants. I am confident that within a few years, more and more ADCs will be used as targeted chemotherapy instead of classic chemotherapy in many cancer cases."



News Source: AA

BioNTech cancer vaccine cancer vaccine Uğur Şahin